Browse IGF2R

Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lysosome membrane Single-pass type I membrane protein Note=Colocalized with DPP4 in internalized cytoplasmic vesicles adjacent to the cell surface.
Domain PF00878 Cation-independent mannose-6-phosphate receptor repeat
PF00040 Fibronectin type II domain
Function

Transport of phosphorylated lysosomal enzymes from the Golgi complex and the cell surface to lysosomes. Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelyosomal compartment where the low pH mediates the dissociation of the complex. This receptor also binds IGF2. Acts as a positive regulator of T-cell coactivation, by binding DPP4.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001889 liver development
GO:0006898 receptor-mediated endocytosis
GO:0007283 spermatogenesis
GO:0009791 post-embryonic development
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0032526 response to retinoic acid
GO:0048009 insulin-like growth factor receptor signaling pathway
GO:0048232 male gamete generation
GO:0048732 gland development
GO:0061008 hepaticobiliary system development
Molecular Function GO:0001948 glycoprotein binding
GO:0001965 G-protein alpha-subunit binding
GO:0001972 retinoic acid binding
GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005010 insulin-like growth factor-activated receptor activity
GO:0005501 retinoid binding
GO:0005520 insulin-like growth factor binding
GO:0005537 mannose binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0019840 isoprenoid binding
GO:0030246 carbohydrate binding
GO:0031406 carboxylic acid binding
GO:0031995 insulin-like growth factor II binding
GO:0033293 monocarboxylic acid binding
GO:0043168 anion binding
GO:0048029 monosaccharide binding
GO:0051219 phosphoprotein binding
Cellular Component GO:0005635 nuclear envelope
GO:0005641 nuclear envelope lumen
GO:0005765 lysosomal membrane
GO:0005769 early endosome
GO:0005770 late endosome
GO:0005798 Golgi-associated vesicle
GO:0005802 trans-Golgi network
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
GO:0030117 membrane coat
GO:0030118 clathrin coat
GO:0030133 transport vesicle
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030140 trans-Golgi network transport vesicle
GO:0031970 organelle envelope lumen
GO:0031984 organelle subcompartment
GO:0032588 trans-Golgi network membrane
GO:0048475 coated membrane
GO:0098791 Golgi subcompartment
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04142 Lysosome
hsa04144 Endocytosis
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-421837: Clathrin derived vesicle budding
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-432722: Golgi Associated Vesicle Biogenesis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-199991: Membrane Trafficking
R-HSA-6798695: Neutrophil degranulation
R-HSA-6811440: Retrograde transport at the Trans-Golgi-Network
R-HSA-5653656: Vesicle-mediated transport
R-HSA-199992: trans-Golgi Network Vesicle Budding
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IGF2R and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IGF2R and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23324210MelanomaPromote immunityWe found that chemotherapy enhanced the levels of insulin-like growth factor 2 receptor/cation-independent mannose-6-phosphate receptor (IGF2R) on the surface of tumor cells, which leads to better tumor targeting by cytotoxic T cells (CTLs)
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IGF2R in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IGF2R in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3010.24
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0170.647
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2240.892
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2150.497
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0490.986
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4260.907
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3520.5
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2380.912
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5150.827
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3350.795
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0320.587
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0940.0766
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IGF2R in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IGF2R. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IGF2R. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IGF2R.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IGF2R. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IGF2R expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IGF2R and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIGF2R
Nameinsulin-like growth factor 2 receptor
Aliases CD222; MPRI; MPR1; CIMPR; M6P-R; cation-independent mannose-6 phosphate receptor; 300 kDa mannose 6-phosphat ......
Chromosomal Location6q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IGF2R collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IGF2R.
ID Name Drug Type Targets #Targets
DB01277MecaserminBiotechIGF1R, IGF2R, IGFBP3, INSR4
DB02900alpha-D-mannose 6-phosphateSmall MoleculeIGF2R, M6PR2
DB13173Cerliponase alfaBiotechIGF2R1